Document:

Exhibit
10.10

 

TRXADE
HEALTH, INC.

 

2019
EQUITY INCENTIVE PLAN 

 

NOTICE
OF RESTRICTED STOCK GRANT

 

Capitalized
but otherwise undefined terms in this Notice of Restricted Stock Grant and the attached Restricted Stock Grant Agreement shall have the
same defined meanings as in the TRxADE HEALTH, INC. Amended and Restated 2019 Equity Incentive Plan (as amended from time to time) (as
amended from time to time, the “Plan”).

 

Grantee
Name:

 

Address:_________________________________________

 

You
have been granted Restricted Stock (“Shares”) subject to the terms and conditions of the Plan and the attached
Restricted Stock Grant Agreement, as follows:

 

	Date
    of Grant:	August
    31, 2022
	 	 
	Vesting
    Commencement Date:	August
    31, 2022 Price 
	 	 
	Per
    Share:	$1.16
	 	 
	Total
    Number of Shares Granted: 	______
	 	 
	Total
    Value of Shares Granted:	$
	 	 
	Total
    Purchase Price:	$0,
    Issued In Consideration For Services 
	 	 
	Agreement
    Date:	August
    31, 2022

 

Vesting
Schedule: 1/4th of the Shares vest on September 1, 2022 and October 1, 2022 and January 1 and April 1, 2023, subject to the terms
of the applicable Restricted Stock Grant Agreement which follows and the Plan.

 

    	Page 1 of 9

Amended and Restated 2019 Equity Incentive Plan Restricted
Stock Grant Agreement

     

    

 

TRXADE
HEALTH, INC.

 

2019
EQUITY INCENTIVE PLAN 

 

RESTRICTED
STOCK GRANT AGREEMENT

 

This
RESTRICTED STOCK GRANT AGREEMENT (“Agreement”), dated as of the Agreement Date specified on the Notice
of Restricted Stock Grant is made by and between TRxADE HEALTH, INC., a Delaware corporation (the “Company”),
and the grantee named in the Notice of Restricted Stock Grant (the “Grantee,” which term as used herein shall
be deemed to include any successor to Grantee by will or by the laws of descent and distribution, unless the context shall otherwise
require).

 

BACKGROUND

 

Pursuant
to the Plan, the Board (or an authorized Committee thereof), approved the issuance to Grantee, effective as of the date set forth above,
of an award of the number of shares of Restricted Stock as is set forth in the attached Notice of Restricted Stock Grant (which is expressly
incorporated herein and made a part hereof, the “Notice of Restricted Stock Grant”) at the purchase price per
share of Restricted Stock (the “Purchase Price”), if any, set forth in the attached Notice of Restricted Stock
Grant, upon the terms and conditions hereinafter set forth.

 

NOW,
THEREFORE, in consideration of the mutual premises and undertakings hereinafter set forth, the parties agree as follows:

 

1.
Grant and Purchase of Restricted Stock. The Company hereby grants to Grantee, and Grantee hereby accepts the Restricted
Stock set forth in the Notice of Restricted Stock Grant, subject to the payment by Grantee of the total purchase price, if any, set forth
in the Notice of Restricted Stock Grant.

 

2.
Stockholder Rights.

 

(a)
Voting Rights. Until such time as all or any part of the Restricted Stock are forfeited to the Company under this Agreement, if
ever, Grantee (or any successor in interest) has the rights of a stockholder, including voting rights, with respect to the Restricted
Stock subject, however, to the transfer restrictions or any other restrictions set forth in the Plan.

 

(b)
Dividends and Other Distributions. During the period of restriction, Participants holding Restricted Stock are entitled to all
regular cash dividends or other distributions paid with respect to all shares while they are so held. If any such dividends or distributions
are paid in shares, such shares will be subject to the same restrictions on transferability and forfeitability as the Restricted Stock
with respect to which they were paid.

 

    	Page 2 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

3.
Vesting of Restricted Stock.

 

(a)
The Restricted Stock are restricted and subject to forfeiture until vested. The Restricted Stock which have vested and are no longer
subject to forfeiture are referred to as “Vested Shares.” All Restricted Stock which have not become Vested
Shares are referred to as “Nonvested Shares.”

 

(b)
Restricted Stock will vest and become nonforfeitable in accordance with the vesting schedule contained in the Notice of Restricted Stock
Grant.

 

(c)
Any Nonvested Shares of Grantee will automatically vest and become nonforfeitable if Grantee’s service with the Company ceases
owing to the Grantee’s Retirement, unless the Board (or an authorized committee thereof) provides otherwise.

 

(d)
In the event of a Change of Control, the Board (or an authorized committee thereof), in its discretion, may accelerate the time at which
all or any portion of Grantee’s Restricted Stock will vest.

 

(e)
Terms used in Section 3 and Section 4 have the following meanings:

 

(i)
“Cause” has the meaning ascribed to such term or words of similar import in Grantee’s written
employment or service contract with the Company or its subsidiaries and, in the absence of such agreement or definition, means
Grantee’s (i) conviction of, or plea of nolo contendere to, a felony or crime involving moral turpitude; (ii) fraud on or
misappropriation of any funds or property of the Company or its subsidiaries, or any affiliate, customer or vendor; (iii) personal
dishonesty, incompetence, willful misconduct, willful violation of any law, rule or regulation (other than minor traffic violations
or similar offenses), or breach of fiduciary duty which involves personal profit; (iv) willful misconduct in connection with
Grantee’s duties or willful failure to perform Grantee’s responsibilities in the best interests of the Company or its
subsidiaries; (v) illegal use or distribution of drugs; (vi) violation of any material rule, regulation, procedure or policy of the
Company or its subsidiaries, the violation of which could have a material detriment to the Company; or (vii) material breach of any
provision of any employment, non-disclosure, non-competition, non-solicitation or other similar agreement executed by Grantee for
the benefit of the Company or its subsidiaries, all as reasonably determined by the Board of Directors of the Company, which
determination will be conclusive.

 

(ii)
“Retirement” means Grantee’s retirement from Company employ at or above the age 65 as determined in accordance
with the policies of the Company or its subsidiaries, if any, in good faith by the Board of Directors of the Company, which determination
will be final and binding on all parties concerned.

 

(f)
Nonvested Shares may not be sold, transferred, assigned, pledged, or otherwise disposed of, directly or indirectly, whether by operation
of law or otherwise. The restrictions set forth in this Section will terminate upon a Change of Control.

 

4. Forfeiture
of Nonvested Shares. Except as provided herein, if Grantee’s service with the Company ceases for any reason (including
Disability) other than Grantee’s (a) Retirement or (b) death, any Nonvested Shares will be automatically forfeited to the
Company for no consideration; unless the Board (or an authorized committee thereof) provides otherwise, and provided, however, that
the Board (or an authorized committee thereof) may cause any Nonvested Shares immediately to vest and become nonforfeitable if
Grantee’s service with the Company is terminated by the Company without Cause.

 

    	Page 3 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

(a)
Legend. Each certificate representing Restricted Stock granted pursuant to the Notice of Restricted Stock Grant may bear a legend
substantially as follows:

 

“THE
SALE OR OTHER TRANSFER OF THE SHARES REPRESENTED BY THIS CERTIFICATE, WHETHER VOLUNTARY, INVOLUNTARY OR BY OPERATION OF LAW, IS SUBJECT
TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE TRXADE HEALTH, INC. 2019 AMENDED AND RESTATED EQUITY INCENTIVE PLAN (AS AMENDED)
AND IN A RESTRICTED SHARE GRANT AGREEMENT. A COPY OF SUCH PLAN AND SUCH AGREEMENT MAY BE OBTAINED FROM TRXADE HEALTH, INC.”

 

(b)
Escrow of Nonvested Shares. The Company has the right to retain the certificates representing Nonvested Shares in the Company’s
possession until such time as all restrictions applicable to such shares have been satisfied.

 

(c)
Removal of Restrictions. The Participant is entitled to have the legend removed from certificates representing Vested Shares.

 

5.
Recapitalizations, Exchanges, Mergers, Etc. The provisions of this Agreement apply to the full extent set forth herein
with respect to any and all shares of capital stock of the Company or successor of the Company which may be issued in respect of, in
exchange for, or in substitution for the Restricted Stock by reason of any stock dividend, split, reverse split, combination, recapitalization,
reclassification, merger, consolidation or otherwise which does not terminate this Agreement. Except as otherwise provided herein, this
Agreement is not intended to confer upon any other person except the parties hereto any rights or remedies hereunder.

 

6.
Grantee Representations.

 

Grantee
represents to the Company the following:

 

(a)
Restrictions on Transfer. Grantee acknowledges that the Restricted Stock to be issued to Grantee must be held indefinitely unless
subsequently registered and qualified under the Securities Act of 1933, as amended (the “Securities Act”) or
unless an exemption from registration and qualification is otherwise available. In addition, Grantee understands that the certificate
representing the Restricted Stock will be imprinted with a legend which prohibits the transfer of such Restricted Stock unless they are
sold in a transaction in compliance with the Securities Act or are registered and qualified or such registration and qualification are
not required in the opinion of counsel acceptable to the Company.

 

(b) Relationship
to the Company; Experience. Grantee either has a preexisting business or personal relationship with the Company or any of its
officers, directors or controlling persons or, by reason of Grantee’s business or financial experience or the business or
financial experience of Grantee’s personal representative(s), if any, who are unaffiliated with and who are not compensated by
the Company or any affiliate or selling agent, directly or indirectly, has the capacity to protect Grantee’s own interests in
connection with Grantee’s acquisition of the Restricted Stock to be issued to Grantee hereunder. Grantee and/or
Grantee’s personal representative(s) have such knowledge and experience in financial, tax and business matters to enable
Grantee and/or them to utilize the information made available to Grantee and/or them in connection with the acquisition of the
Restricted Stock to evaluate the merits and risks of the prospective investment and to make an informed investment decision with
respect thereto.

 

    	Page 4 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

(c)
Grantee’s Liquidity. In reaching the decision to invest in the Restricted Stock, Grantee has carefully evaluated Grantee’s
financial resources and investment position and the risks associated with this investment, and Grantee acknowledges that Grantee is able
to bear the economic risks of the investment. Grantee (i) has adequate means of providing for Grantee’s current needs and possible
personal contingencies, (ii) has no need for liquidity in Grantee’s investment, (iii) is able to bear the substantial economic
risks of an investment in the Restricted Stock for an indefinite period and (iv) at the present time, can afford a complete loss of such
investment. Grantee’s commitment to investments which are not readily marketable is not disproportionate to Grantee’s net
worth and Grantee’s investment in the Restricted Stock will not cause Grantee’s overall commitment to become excessive.

 

(d)
Access to Data. Grantee acknowledges that during the course of this transaction and before deciding to acquire the Restricted
Stock, Grantee has been provided with financial and other written information about the Company. Grantee has been given the opportunity
by the Company to obtain any information and ask questions concerning the Company, the Restricted Stock, and Grantee’s investment
that Grantee felt necessary; and to the extent Grantee availed himself/herself of that opportunity, Grantee has received satisfactory
information and answers concerning the business and financial condition of the Company in response to all inquiries in respect thereof.

 

(e) Risks.
Grantee acknowledges and understands that (i) an investment in the Company constitutes a high risk, (ii) the Restricted Stock are
highly speculative, and (iii) there can be no assurance as to what investment return, if any, there may be. Grantee is aware that
the Company may issue additional securities in the future which could result in the dilution of Grantee’s ownership interest
in the Company.

 

(f)
Valid Agreement. This Agreement when executed and delivered by Grantee will constitute a valid and legally binding obligation
of Grantee which is enforceable in accordance with its terms.

 

(g)
Residence. The address set forth on the Notice of Restricted Stock Grant is Grantee’s current address and accurately sets
forth Grantee’s place of residence.

 

(h)
Tax Consequences. Grantee has reviewed with Grantee’s own tax advisors the federal, state, local and foreign tax consequences
of this investment and the transactions contemplated by this Agreement. Grantee is relying solely on such advisors and not on any statements
or representations of the Company or any of its agents. Grantee understands that Grantee (and not the Company) is responsible for Grantee’s
own tax liability that may arise as a result of the transactions contemplated by this Agreement. Grantee understands that Section 83
of the Internal Revenue Code of 1986, as amended (the “Code”), taxes as ordinary income the difference between
the purchase price for the Restricted Stock and the fair market value of the Restricted Stock as of the date any restrictions on the
Restricted Stock lapse. Grantee understands that Grantee may elect to be taxed at the time the Restricted Stock is purchased rather than
when and as the restrictions lapse by filing an election under Section 83(b) of the Code with the Internal Revenue Service within 30
days from the date of purchase. The form for making this election is attached as Exhibit A hereto.

 

    	Page 5 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

GRANTEE
ACKNOWLEDGES THAT IT IS GRANTEE’S SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY ANY ELECTION UNDER SECTION 83(b),
EVEN IF GRANTEE REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON GRANTEE’S BEHALF.

 

7.
No Employment Contract Created. The issuance of the Restricted Stock is not to be construed as granting to Grantee any
right with respect to continuance of employment or any service with the Company or any of its subsidiaries. The right of the Company
or any of its subsidiaries to terminate at will Grantee’s employment or terminate Grantee’s service at any time (whether
by dismissal, discharge or otherwise), with or without cause, is specifically reserved, subject to any other written employment or other
agreement to which the Company and Grantee may be a party.

 

8.
Tax Withholding. The Company has the power and the right to deduct or withhold, or require Grantee to remit to the Company,
an amount sufficient to satisfy Federal, state and local taxes (including the Grantee’s FICA obligation) required by law to be
withheld with respect to the grant and vesting of the Restricted Stock.

 

9.
Interpretation. The Restricted Stock are being issued pursuant to the terms of the Plan, and are to be interpreted in accordance
therewith. The Board (or an authorized committee thereof) will interpret and construe this Agreement and the Plan, and any action, decision,
interpretation or determination made in good faith by the Board (or an authorized committee thereof) will be final and binding on the
Company and Grantee.

 

10.
Notices. All notices or other communications which are required or permitted hereunder will be in writing and sufficient
if (i) personally delivered or sent by telecopy, (ii) sent by nationally-recognized overnight courier or (iii) sent by registered or
certified mail, postage prepaid, return receipt requested, addressed as follows:

 

(a)
if to the Grantee, to the address (or telecopy number) set forth on the Notice of Grant; and

 

(b)
if to the Company, to its principal executive office as specified in any report filed by the Company with the Securities and Exchange
Commission or to such address as the Company may have specified to the Grantee in writing, Attention: Corporate Secretary;

 

or
to such other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith.
Any such communication will be deemed to have been given (i) when delivered, if personally delivered, or when telecopied, if telecopied,
(ii) on the first Business Day (as hereinafter defined) after dispatch, if sent by nationally-recognized overnight courier and (iii)
on the fifth Business Day following the date on which the piece of mail containing such communication is posted, if sent by mail. As
used herein, “Business Day” means a day that is not a Saturday, Sunday or a day on which banking institutions
in the city to which the notice or communication is to be sent are not required to be open.

 

    	Page 6 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

11.
Specific Performance. Grantee expressly agrees that the Company will be irreparably damaged if the provisions of this Agreement
and the Plan are not specifically enforced. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Agreement
or the Plan by Grantee, the Company will, in addition to all other remedies, be entitled to a temporary or permanent injunction, without
showing any actual damage, and/or decree for specific performance, in accordance with the provisions hereof and thereof. The Board (or
an authorized committee thereof) has the power to determine what constitutes a breach or threatened breach of this Agreement or the Plan.
Any such determinations will be final and conclusive and binding upon Grantee.

 

12.
No Waiver. No waiver of any breach or condition of this Agreement will be deemed to be a waiver of any other or subsequent
breach or condition, whether of like or different nature.

 

13.
Grantee Undertaking. Grantee hereby agrees to take whatever additional actions and execute whatever additional documents
the Company may in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations
or restrictions imposed on Grantee pursuant to the express provisions of this Agreement.

 

14.
Modification of Rights. The rights of Grantee are subject to modification and termination in certain events as provided
in this Agreement and the Plan.

 

15.
Governing Law. This Agreement is governed by, and construed in accordance with, the laws of the State of Delaware, without
giving effect to its conflict or choice of law principles that might otherwise refer construction or interpretation of this Agreement
to the substantive law of another jurisdiction.

 

16.
Counterparts; Facsimile Execution. This Agreement may be executed in one or more counterparts, each of which will be deemed
to be an original, but all of which together will constitute one and the same instrument. Facsimile execution and delivery of this Agreement
is legal, valid and binding execution and delivery for all purposes.

 

17.
Entire Agreement. This Agreement (including the Notice of Restricted Stock Grant) and the Plan, constitute the entire agreement
between the parties with respect to the subject matter hereof, and supersedes all previously written or oral negotiations, commitments,
representations and agreements with respect thereto.

 

18.
Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this
Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

 

19. WAIVER
OF JURY TRIAL. THE GRANTEE HEREBY EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR
PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN.

 

[Signature
Page Follows]

 

    	Page 7 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Restricted Share Grant Agreement as of the date first written above.

 

	TRXADE
    HEALTH, INC. 	 
	 	 
	By:	 	 
	 	 	 
	Name:	Suren
    Ajjarapu	 
	 	 	 
	Title:	CEO	 
	 	 	 
	GRANTEE:
    	 
	 	 	 
	 	 	 
	 	 	 
	Name:	 	 

 

    	Page 8 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

SPOUSE'S
CONSENT TO AGREEMENT

(Required
where Grantee resides in a community property state)

 

I
acknowledge that I have read the Agreement and the Plan and that I know and understand the contents of both. I am aware that my spouse
has agreed therein to the imposition of certain forfeiture provisions and restrictions on transferability with respect to the Restricted
Stock that are the subject of the Agreement, including with respect to my community interest therein, if any, on the occurrence of certain
events described in the Agreement. I hereby consent to and approve of the provisions of the Agreement, and agree that I will abide by
the Agreement and bequeath any interest in the Restricted Stock which represents a community interest of mine to my spouse or to a trust
subject to my spouse’s control or for my spouse’s benefit or the benefit of our children if I predecease my spouse.

 

	Dated:	 	 
	 	 	 
	Signature:	 	 
	 	 	 
	Print
    Name:	 	 

 

    	Page 9 of 9

2019 Equity Incentive Plan Restricted Stock Grant Agreement

     

    

 

ELECTION
UNDER SECTION 83(b)

OF
THE INTERNAL REVENUE CODE OF 1986

 

The
undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in the taxpayer’s
gross income or alternative minimum taxable income, as the case may be, for the current taxable year, as compensation for services the
excess (if any) of the fair market value of the shares described below over the amount paid for those shares:

 

1.
The name, address, taxpayer identification number and taxable year of the undersigned are as follows:

 

Taxpayer:

Spouse:

Name:

Address:

Identification
No.:

Taxable
Year:

 

2.
The property with respect to which the election is made is described as follows:_____________shares (the “Shares”)
of the Common Stock of TRxADE HEALTH, INC., a Delaware corporation (the “Company”).

 

3.
The date on which the property was transferred is: ____________________,________ .

 

4.
The property is subject to the following restrictions: The Shares may not be transferred and are subject to forfeiture under the terms
of an agreement between the taxpayer and the Company. These restrictions lapse upon the satisfaction of certain conditions contained
in such agreement.

 

5.
The fair market value of the property at the time of transfer (determined without regard to any restriction other than a nonlapse restriction
as defined in § 1.83-3(h) of the Income Tax Regulations) is:

$
______ per share x ______ shares = $ _________.

 

6.
For the property transferred, the undersigned paid $ ______ per share x _______ shares= $ _____________.

 

7.
The amount to include in gross income is $ _______________. [The result of the amount reported in Item 5 minus the amount reported in Item 6.]

 

The
undersigned taxpayer will file this election with the Internal Revenue Service office with which taxpayer files his or her annual income
tax return not later than 30 days after the date of transfer of the property. A copy of the election also will be furnished to the person
for whom the services were performed. Additionally, the undersigned will include a copy of the election with his or her income tax return
for the taxable year in which the property is transferred. The undersigned is the person performing the services in connection with which
the property was transferred.

 

The
undersigned understands that the foregoing election may not be revoked except with the consent of the Commissioner.

 

	Dated:
____________________, _________   	 
	 	 
	__________________________	 
	Taxpayer	 
	 	 
	The
    undersigned spouse of taxpayer joins in this election.	 
	 	 
	 Dated:_____________________, _______	 
	 	 
	__________________________	 
	Spouse
    of TaxpayerExhibit 10.1

  

   

  

   

  

  
    August 24, 2022

    

    

    Kevin D’Amour 

    Via email

     

    
      	 	
              RE:

            	
              Separation Agreement and General Release

            

    

     

    Dear Kevin:

     

    The purpose of this separation agreement (the “Separation Agreement”)
        is to memorialize the terms and conditions of the separation of your employment with Brooklyn ImmunoTherapeutics, Inc. (the “Company”) and its subsidiaries and affiliates (together with the Company collectively, the “Company

          Group”), as well as that certain Executive Employment Agreement, dated June 5, 2021, by and between YOU (the terms “YOU” and “YOUR” refers to Kevin D’ Amour) and the Company (the “Employment Agreement”). Capitalized

        terms used but not defined here in shall have the meanings ascribed thereto in the Employment Agreement.

     

    To ensure that YOUR separation from the Company occurs on mutually acceptable terms,
        this Separation Agreement, along with the General Release of Claims on Exhibit A, attached

        hereto and made a part hereof (the “General Release”), will summarize the terms and conditions surrounding YOUR separation including, without limitation, the compensation, and benefits that will be provided
        to YOU.

     

    Separation Date

     

    The effective date of the separation of YOUR employment, and the Employment Agreement,
        is August 26, 2022 (“Separation Date”).

     

    Resignation as Officer and Director of the Company Group

     

    YOU acknowledge and agree that, effective as of the Separation Date, YOU will be deemed
        to have resigned from all positions then held as an officer as well as a member of any board of directors, and any committee thereto, throughout the Company Group.

    

    

    Accrued Obligations

    

    

    Whether or not YOU choose to sign this Separation Agreement and the General Release,
        the Company will pay to YOU any (a) accrued but unpaid base salary YOU have earned through the Separation Date, (b) accrued but unused paid time off through the Separation Date (c) reimbursement for unreimbursed business expenses properly incurred
        by YOU pursuant to the Company’s applicable expense reimbursement policy; and (d) any accrued but unpaid benefits provided under the Company’s employee benefit plans, subject to and in accordance with the terms of those plans, in each case, less
        applicable withholding and employment taxes, all of which shall be paid to YOU by the Separation Date or such other date as required under the applicable employee benefit plan.

     

    
      
        

    

    
    For purposes of this Separation Agreement and the General Release, the amounts
        described above in this section shall be referred to as the “Accrued Obligations”.

    

    

    Separation Benefits

     

    In the event that YOU execute and deliver to the Company both the Separation Agreement
        and the General Release, and YOU do not revoke the General Release within the time period permitted by law (such period, the  “Revocation  Period”  as  defined  below), the following shall apply (subject to any timing
        restrictions as may be applicable under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)):

     

    
      
        	 	
                ●

              	
                Commencing on the first regular payroll date immediately following the end of the Revocation
                    Period, the Company shall continue to pay to YOU YOUR annual base salary for a period of nine (9) months thereafter (the “Severance Period”) in accordance with the Company’s normal payroll processing, for a total gross
                    amount equal to $311,250 (less applicable income and employment tax withholdings).

              

      

    

     

    	

          	●	
            If YOU (or YOU and YOUR eligible dependents) timely and properly elects health insurance
                continuation rights under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company will pay the cost of the COBRA premiums until the earlier of (i) the last day of the Severance Period or (ii) the termination of
                YOUR rights  under COBRA;  provided,  for the avoidance of doubt, that such covered dependents participated in the Company’s health plans prior to such separation, and provided, further, that if at any time the Company determines that its
                payment of YOUR (or YOUR eligible dependents’ ) premiums would result in a violation of law, then in lieu of providing the premiums described above, the Company will instead pay YOU a fully taxable  monthly cash  payment in an amount equal
                to the applicable premiums for such month, with such monthly payment being made on the last day of each month for the remainder of the Severance Period.

          

     

    

    For purposes of this Separation Agreement and the General Release, the benefits
        described above in this section shall be referred to as the “Separation Benefits”. Except for the Accrued Obligations, the payments from the Company to YOU pursuant to the terms of this Separation Agreement (including
        the Separation Benefits) are not provided as a raise, bonus, or condition of YOUR employment with the Company.

    

    

    

    

    

    

    

    

    10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com 

    Mailing address: 10531 4S Commons
        Drive, Suite 160-550, San Diego, CA 92127

     

      

    
      2

      
        

    

    YOU acknowledge and agree that as of the Separation Date,  this Separation  Agreement 
        and General Release shall supersede and replace all benefits, rights and obligations in connection with YOUR employment with the Company Group, except for those terms in the Employment Agreement that are specifically restated herein. Accordingly,
        YOU further acknowledge and agree that this Separation Agreement and the General  Release sets forth  all  compensation  and  benefits to which YOU are entitled and shall be paid to YOU in full satisfaction thereof, in connection with your
        employment with the Company Group.

     

    YOU also acknowledge and agree that the Separation Benefits to be paid under this
        Agreement is due solely from the Company and that Insperity PEO Services, L.P. (“Insperity”), the professional employer organization retained by the Company, has no obligation to pay the Severance
        benefits, even though its payment may be processed through Insperity.

     

    Equity Awards

     

    YOU acknowledge and agree that as of the Separation Date:

     

    

    	

          	●	
            The vested portion of the Option Grant (which specifically relates to 38,074 shares of  the  Company) shall  be eligible to be exercised  for a period of
                ninety (90) days after the Separation Date pursuant to the terms and conditions of the Option Grant. The remainder of the Option Grant (which relates specifically to 102,506 shares of the Company) is unvested and shall be immediately forfeited as of the Separation Date.

          

     

    	

          	●	
            The unvested portion of the RSU Grant, which specifically relates to 52,717 shares of the Company, shall be immediately forfeited as of the Separation Date.
                The vested portion of the RSU Grant, which specifically related to 17,573 shares

                of the Company were previously vested pursuant to the terms and conditions of the RSU Grant.

          

     

    	

          	●	
            The outstanding portion of the performance stock units granted to YOU on March 11, 2022 (the “2022

                PSU Award”), which specifically relates to 103,800 shares of the
                Company, is unvested and shall be immediately forfeited as of the Separation Date. The remainder of the 2022 PSU Award, which specifically related to 34,600 shares of the Company, were previously forfeited prior to the Separation Date pursuant to the terms and condition of the 2022 PSU Award.

          

    

    

    	

          	●	
            The vested portion of the stock option granted to YOU on March 11, 2022 (the “2022
                  Option”) (which specifically relates to 19,222 shares of the
                Company) shall be eligible to be exercised for a period of ninety (90) days after  the  Separation Date pursuant to the terms and conditions of the applicable stock option award agreement. The remainder of the 2022 Option (which relates
                specifically to 119,178 shares of the Company) is unvested and shall be
                immediately forfeited as of the Separation Date.

          

     

    
       

      

       

      

       

      

      10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com 

      Mailing address: 10531 4S Commons
          Drive, Suite 160-550, San Diego, CA 92127

    

     

      

    
      3

      
        

    

    You acknowledge and agree that you do not have any rights with respect to any other
        equity awards or equity-based interests in the Company.

     

    Agreement Preparation and Negotiation Fees

     

    Upon submission of invoices and other applicable documentation reasonably requested by
        the Company, the Company shall  reimburse you for reasonable  attorneys’  fees and costs incurred by you in connection with your separation including the preparation and negotiation of this Separation Agreement and General Release, up to a maximum
        amount of $5,000.

     

    Integration of Employment Agreement; Survival of Certain Provisions

     

    As of the Separation Date, YOU acknowledge and agree that this Separation Agreement shall supersede and replace the Employment
        Agreement, except for those provision that are specifically restated and incorporated by reference herein, in addition to the following provisions under the Employment Agreement (collectively, the “Survival Provisions”):
        Section 6 (Company Property) provided you will be entitled to keep and not obligated to return to the Company your work laptop so long as all of the Company property, documents and confidential information are removed from such laptop; Section 9
        (Protection of Confidential Information); Section 10 (Intellectual Property); Section 11 (Publicity; Non-disparagement), except the parties agree that nothing in this Separation Agreement or the Employment Agreement prevents YOU from discussing or
        disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that YOU have reason to believe is unlawful; Section 20 (Dispute Resolution) and Section 21 (Indemnification) which shall
          remain in full force and effect except the parties agree that (a) individual claims under the Private Attorneys General Act can be subject to arbitration under that Section 20 and (b) the following claims are
        excluded from the scope of that Section 20: (i) claims under the National Labor Relations Act, (ii) claims under the California Workers’ Compensation Act, (iii) claims for unemployment compensation benefits, (iv) claims for benefits under a plan that is governed by the Employee Retirement Income Security Act of 1974, (v) claims that are subject to the Ending
          Forced Arbitration of Sexual Assault and Sexual Harassment Act, or (vi) claims that are expressly prohibited from mandatory arbitration under applicable law. Accordingly, YOU further acknowledge and agree that (i) this Separation Agreement sets
          fo1th all compensation and benefits to which YOU are  entitled  under  YOUR Employment Agreement; and (ii) in the event that YOU breach any of the Survival Provisions, the Separation Benefits shall cease immediately and YOU will no longer be
          entitled to such benefits.

    

    

    Release Of Claims Against The Company Group

    

    

    In exchange  for  and  as a condition to receiving  the Separation Benefits, YOU  shall
        knowingly and willingly release the Company Group from any kind of claim YOU have arising out of or related to YOUR employment, the Employment Agreement and/or the termination of YOUR employment with the Company Group by executing the General
        Release attached hereto as Exhibit A.

     

    
       

      

       

      

       

      

      10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com 

      Mailing address: 10531 4S Commons
          Drive, Suite 160-550, San Diego, CA 92127

    

     

      

    
      4

      
        

    

    YOU will be required to execute the General Release, and therefore
        agree to be bound by the terms and conditions thereof, no earlier than the Separation Date but no later than thirty (30) days after such Separation Date.

     

    Cooperation/Assistance

     

    Cooperation and Assistance: Upon
        reasonable notice  and at reasonable times, YOU agree to assist and cooperate with the Company, by telephone or video conference or otherwise, concerning business or legal related matters about which YOU possess relevant knowledge or information.
        Such cooperation shall only be provided at the Company’s specific request and will include, but not be limited to, assisting or advising the Company with respect to any  business-related matters or any actual or threatened legal action (including
        testifying in depositions, hearings, and /or trials) about which YOU possess relevant knowledge or information. In addition, you agree to promptly inform the Company if any person or entity contacts YOU in an effort to obtain information about the
        Company. The Company agrees to reimburse YOU for all reasonable and necessary costs and expenses incurred in connection with such cooperation and will compensate YOU at a reasonable rate for time spent by YOU at the Company’s request in connection
        with such cooperation.

     

    Severability; Entire Agreement; No Oral Modifications;

        No Waivers

     

    If a court of competent jurisdiction determines that any of the provisions of this
        Agreement are invalid or legally unenforceable, all other provisions of this Agreement shall not be affected and are still enforceable. This Separation Agreement and the General Release are intended to be a single integrated contract expressing our
        entire understanding regarding  the subjects  it addresses. As such, it supersedes all oral and written agreements, promises, representations  and discussions that occurred before the time YOU sign each of them except as to any obligations YOU may
        owe to the Company Group as described in the “Integration of Employment Agreement; Survival of Certain Provisions” section above that remain in effect and for the avoidance of doubt, no extrinsic evidence may be introduced in any judicial proceeding or arbitration involving this Separation Agreement. This Separation Agreement and
        the General Release may be amended or modified only by an agreement in writing signed by YOU and counter signed by an executive officer of the Company. The failure by the Company or YOU (i) to declare a breach, or (ii) to otherwise assert rights
        under this Agreement shall not be construed as a waiver of any of rights under this Separation Agreement and the General Release. This Separation Agreement and the General Release may be executed and delivered (including by facsimile or other
        electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same
        instrument.

    

    

     

    

     

    

     

    

    10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com 

    Mailing address: 10531 4S Commons
        Drive, Suite 160-550, San Diego, CA 92127

     

      

    
      5

      
        

    

    Governing Law; Venue

     

    This Separation Agreement and the General Release shall be governed by the laws of the 
        State of California applicable to contracts executed  and  performed  within  that State and  without respect to conflict of laws principles. The parties hereto irrevocably and unconditionally (i) agree that any suit, action or legal proceeding
        arising out  of or relating to  this Agreement shall be brought in the courts of record of the State of California or the court of  the United States, Southern  District of California; and (ii) consent to the jurisdiction of each such court in any
        suit, action  or proceeding.

    

    

    Acknowledgements and Certifications

     

    YOU acknowledge and certify that:

     

    	

          	●	
            YOU have read and YOU understand all of the terms of this Separation Agreement and the General
                Release on Exhibit  A, and are  not  relying  on  any  representation or
                statement, written or oral, not set forth in this Separation Agreement and the General Release;

          

     

    	

          	●	
            YOU are signing this Separation Agreement, and shall sign the General Release, knowingly and
                voluntarily;

          

     

    	

          	●	
            YOU have been advised to consult with an attorney before signing this Separation Agreement and the
                General Release ;

          

     

    	

          	●	
            YOU have the right to consider the terms of this Separation Agreement and the General Release for
                21 days; however, YOU do not have to take all  21 days to consider it, and if YOU take fewer than 21 days to review this Separation Agreement and the General Release,  YOU  expressly waive any and  all  rights to consider this Separation
                Agreement and the General Release for the balance of the 21-day review period; and

          

    

    

    	

          	●	
            the General Release includes a release of any claim YOU might have under the ADEA (the “ADEA Claims”).
                For seven (7) days  after signing  the  General Release, YOU have the right to revoke YOUR release of ADEA Claims (the “Revocation Period”). To revoke YOUR release  of  ADEA Claims, the revocation or rescission
                must be in writing and must be delivered by hand or sent by certified mail , return receipt requested, postmarked with in the seven (7) day period, and properly addressed to the Chairman of the Company at  10355 Science Center Drive,

              Suite 150, San Diego, CA 92121. Revoking YOUR release of ADEA Claims shall result in the invalidation of this Separation Agreement, in its entirety, as of such revocation date; and

          

     

    

     

    

     

    

    10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com 

    Mailing address: 10531 4S Commons
        Drive, Suite 160-550, San Diego, CA 92127

     

    

    
      6

      
        

    

     
      	

            	●	
              YOU and the Company and Parent each agree that any changes that have been made to this Separation Agreement and the General Release from the versions
                originally presented to YOU do not extend the 21-day period YOU have been given to consider this Separation Agreement and the General Release, whether those changes are deemed material or non-material.

            

       

      IF YOU SIGN THIS DOCUMENT AND EXHIBIT A ATTACHED HERETO, IT BECOMES A LEGALLY ENFORCEABLE AGREEMENT EFFECTIVE ON THE DATE SIGNED
        BY THE COMPANY.

       

    

    
      	
              Dated:  August 26, 2022

            	
              /s/ KEVIN D’AMOUR

            	 
	

            	
              
                KEVIN D’AMOUR

              

            

      

      

      	
              Dated:  August 26, 2022

            	
              BROOKLYN IMMUNOTHERAPEUTICS, INC.

              

            
	

            	

            
	

            	By:	/s/ Matt Angel	 
	

            	Name: Matt Angel

            
	

            	Title: CEO

            

    

    

    

    

    

    

    

    

    
      
        10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com 

        Mailing address: 10531 4S Commons
            Drive, Suite 160-550, San Diego, CA 92127

      

       

        

    

    
      7

      
        

    

    
    EXHIBIT A

    

    

    GENERAL RELEASE OF CLAIMS

     

    1.             In exchange for the Separation Benefits described in that certain Separation  and Release Agreement (the “Company”),  dated  August 24, 2022  (the  “Separation  Agreement”) 
          to which this General Release of Claims is attached as Exhibit A thereto, Kevin  D’Amour (“Executive”), for himself and his family, heirs, executors, administrators,  legal  representatives and their respective
          successors and assigns, does hereby release and forever discharge Brooklyn ImmunoTherapeutics, Inc. (the “Company”) and its subsidiaries, affiliated companies, successors and assigns (to get her with Company, the “Company
          Group”) and  Insperity PEO Services, L.P., the professional employer organization retained by the Company, and its current and former parent companies, subsidiaries and other affiliates (collectively, “Insperity”), and

          their respective current or former directors, officers, employees, shareholders, insurers or agents in such capacities (collectively with the Company Group and Insperity, the “Released  Parties”) 
          from  any  and  all actions, causes of action, suits, controversies, claims and demands whatsoever, for or  by reason  of any matter, cause or thing whatsoever, whether known  or unknown  including,  but  not limited  to, all claims under any
          applicable laws arising under or in connection with Executive’s employment or termination thereof, and/or in connection with or arising under the Employment Agreement (as defined in the Separation Agreement), whether for tort, breach of express
          or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment. Executive acknowledges that the Company Group
          encouraged him to consult  with  an  attorney  of  his  choosing,  and  through  this General Release of Claims encourages him to consult with his attorney with respect to possible claims under the Age Discrimination in Employment  Act (“ADEA’’) and

          that he understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the  basis  of  age in  employment and employee benefits and benefit plans. Without limiting the generality of the release provided
          above, Executive expressly waives any and all claims under ADEA that he may have as of the date hereof. Executive further understands that by signing this General Release of Claims he  is  in fact waiving,  releasing and forever giving  up any
          claim  under the  ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to  the  contrary, this  General  Release  of Claims shall
          not apply to (i) any rights to receive any payments or  benefits pursuant to the Separation Agreement, (ii) any rights or claims that may arise as a  result of events occurring after the date this General Release of Claims is executed, (iii) any
          indemnification  rights  Executive may have as a former officer or director of the Company Group, (iv) any claims for benefits under any directors’ and officers’ liability policy maintained  by the Company Group in accordance with the terms of
          such policy, (v) any indemnification rights set forth in the parties’ prior Employment Agreement; and (vi) any rights as a holder of equity securities of the Company.

     

    2              Executive represents that he has not  filed  against  the  Released  Parties  any complaints, charges, or  lawsuits arising out of his employment or under his Employment Agreement, or any
          other matter arising on  or  prior to the date of this  General  Release  of  Claims, and covenants and agrees that he will never individually or with any person file, or commence the filing of, any charges, lawsuits, complaints or proceedings
          with any governmental agency, or against the Released Parties with respect to any of the matters released by Executive pursuant to paragraph 1 hereof (a “Proceeding”); provided, however,
        that

     

    
      A-1

      
        

    

    a               Nothing in this Agreement prohibits or prevents the  Executive from  filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal 
          Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal, state or local anti-discrimination laws. However, to the maximum extent permitted by law, the Executive agrees that if such an
          administrative claim is made to such an anti-discrimination agency, he shall not be entitled  to  recover any individual monetary relief  or  other  individual remedies. In addition, nothing in this Agreement, including but not limited to the
          release of claims and non-disparagement clauses, prohibits the Executive from (A) reporting possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but
          not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (B) making any other disclosures that are protected under the whistleblower provisions of federal law
          or regulations; or (C) otherwise fully participating in any federal whistleblower programs, including but  not  limited to any such programs managed by the U.S. Securities and Exchange Commission and/or the Occupational Safety and Health
          Administration. Moreover, nothing in this Agreement prohibits or prevents the Executive from receiving individual monetary awards or other individual relief by virtue of participating in such federal whistleblower programs.

     

    b.           Executive shall not have relinquished his right to
        commence a Proceeding to challenge whether Executive knowingly and voluntarily waived his rights under ADEA.

    

    

    3.             Executive acknowledges that Executive has been advised to consult with legal counsel and is familiar with the provisions of California Civil Code section 1542, a statute that otherwise prohibits the release of unknown Claims,
          which provides as follows:

     

    A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES
        NOT KNOW OR SUSPECTS TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR THE RELEASED PARTY.

     

    Being aware of said code section, Executive agrees to expressly waive any rights
        Executive may have thereunder, as well as under any other statute or common law  principles of similar effect.

     

    
      A-2

      
        

    

    4.            Executive here by acknowledges that the Company Group has informed him that he has up to twenty-one (21) days to sign this General Release of Claims and he may knowingly and voluntarily waive that twenty-one (21) day period by
          signing this General Release of Claims earlier. Executive also understands that he shall have seven (7) days following the date on which he signs this General Release of Claims within which to revoke the release of ADEA claims by
        providing written notice of his revocation to the Company Group (the “Revocation Period”).

    
       

      

      5.          Executive acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of California applicable to contracts made and to be performed
            entirely within such State.

       

      6.           Executive acknowledges that he has read this General Release of Claims,
          that he has been advised that he should consult with an attorney before he executes this General Release of Claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the
          consequences thereof.

       

      7.           This General Release of Claims shall take effect on the eighth day
          following Executive’s execution of this General Release of Claims unless Executive delivers written revocation(s) to the Company within the aforementioned Revocation Period.

      

      

      
        	
                 

              	/s/ KEVIN D’AMOUR
	
                 

              	KEVIN D’AMOUR

              
	
                 

              	
                 

              
	August 26, 2022

              	
                 

              

      

      

      

      

      

      A-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]